Established from a primary, invasive, ductal breast carcinoma (TNM stage IIa, tumor size 5, grade 3, without lymph node metastasis) from a 52-year-old white woman prior to therapy in 1994; a paired EBV+ B-lymphoblastoid cell line (B-LCL HCC-1143BL) is available; reported to express EGP2, CK19 buth neither estrogen nor progesterone receptors are expressed